Tartrate salt of a substituted spiro[5H-Thieno[2,3-c]Pyran-7,4'-Piperidine compound

Abstract

A tartrate salt of an ORL-1 receptor antagonist of the formula: wherein R1 is fluoro or chloro; R2a and R2b are each hydrogen or are each fluoro; R3 is hydrogen, methyl, hydroxymethyl, or (C-1-C3) alkoxymethyl; R4 is selected from the group consisting of fluoro, chloro, cyano, cyanomethyl, (C1-C3) alkyl, cyclopropyl, hydroxymethyl, methoxy, cyclopropylmethoxy, am inocarbonylmethoxy, (C1-C3) alkoxymethyl, cyclopropyloxymethyl, cyclopropylmethoxymethyl, 1-hydroxy-1-methylethyl, aminocarbonyloxymethyl, methylaminocarbonyloxymethyl, dimethylaminocarbonyloxymethyl, aminocarbonyl, aminocarbonylmethyl, -CH2-NR5R6, hydroxyimine, methoxyimine, morpholin-4-yl, morpholin-4-ylmethyl, Art, -CH2Ar1, tetrahydrofuran-2-yl, 3-oxomorpholin-4- ylmethyl, 2-oxopyrrolidin-1-ylmethyl, and 2-oxopiperidin-l-ylmethyl; R5 is hydrogen, C1-C3 alkyl, cyanomethyl, -C(O)CH3, or aminocarbonylmethyl; R6 is hydrogen or methyl; and Ar1 is a moiety selected from the group consisting of imidizol-l-yl, imidizol-2-yl, 2-methyl imidizol-1 -yl, pyrazol- 1 -yl, 1,2,3-triazol-1 -yl; 1,2,3-triazol-2-y1; 1,2,4 triazol-1 - yl, isoxazol-3-yl, oxazol-5-yl, and 3-methyl-1,2,4-oxadiazol-5-y1; and methods for its preparation are described.